Raptor Pharmaceutical Corp said it plans to advance development of its brain disorder drug to a registration study, despite it failing to show statistical significance in a trial. The drug, RP103, is being evaluated in patients with Huntington’s Disease, a type of neurodegenerative genetic disorder that affects muscle coordination and leads to mental decline and […]